Business Standard

Sandoz shuts unit near Mumbai

Sushmi Dey  |  New Delhi 

Sandoz, the generic arm of Swiss drug maker Novartis, recently closed its facility developing active pharmaceutical ingredients (API) near Mumbai, a person close to the development told Business Standard. This facility was part of the company’s global development centre in India.

confirmed the move. In response to an e-mail query, India Vice-Chairman & Managing Director said, “The decision was taken as part of a project portfolio optimisation within Global Development.”

According to the source, however, financial pressure on the parent company triggered the move. “The facility employed 50 odd people, and most of them were asked to look for jobs,” he said.

Shahani maintained the impact on employees was minimised by redeploying people in other parts of the company here.

Global Development in India employed around 200-250 people, of which 50, who were engaged in API development activities in Kalwa near Mumbai, were given three-months' notice in April, the source said. Although the company retained its formulation development activities and employees engaged in the same, the closure of API development in India happened around June-July, he said.

While Sandoz’s API development activities from India are now consolidated into two other development centres in Europe, the company continues to have its presence in India through development, manufacturing and commercial operations in the formulation segment.

According to a trade source, Sandoz’s popular brands in India include Calcium Sandoz, Adelphane, Curam, Ebutol, etc.

According to a sector analyst, though the move is astonishing as India is a low-cost destination for API development, in the case of it may be relatively less significant as the company would be looking at captive use. “might have done a cost-benefit analysis which suggested the move,” he said. “This could be because the company aims to focus on drug development and R&D in formulations. In that case, it makes sense for the company to even get API from others, it will save them a lot of energy and resources. Plus, the focus will remain on formulations.”

Of the country’s Rs 65,000-crore pharma market, 15 per cent is accounted for by API. Although over the last few years, increasing API imports from China has posed significant threat to the Indian API market, various drug makers like Dr Reddy’s Labs, Cipla and Ranbaxy are still manufacturing both APIs and formulations. However, many of these companies have reduced their focus on API as landed price for some Chinese APIs in India is less than their corresponding cost of production here.

RECOMMENDED FOR YOU

Sandoz shuts unit near Mumbai

Sandoz, the generic arm of Swiss drug maker Novartis, recently closed its facility developing active pharmaceutical ingredients (API) near Mumbai, a person close to the development told Business Standard. This facility was part of the company’s global development centre in India.

Sandoz, the generic arm of Swiss drug maker Novartis, recently closed its facility developing active pharmaceutical ingredients (API) near Mumbai, a person close to the development told Business Standard. This facility was part of the company’s global development centre in India.

confirmed the move. In response to an e-mail query, India Vice-Chairman & Managing Director said, “The decision was taken as part of a project portfolio optimisation within Global Development.”

According to the source, however, financial pressure on the parent company triggered the move. “The facility employed 50 odd people, and most of them were asked to look for jobs,” he said.

Shahani maintained the impact on employees was minimised by redeploying people in other parts of the company here.

Global Development in India employed around 200-250 people, of which 50, who were engaged in API development activities in Kalwa near Mumbai, were given three-months' notice in April, the source said. Although the company retained its formulation development activities and employees engaged in the same, the closure of API development in India happened around June-July, he said.

While Sandoz’s API development activities from India are now consolidated into two other development centres in Europe, the company continues to have its presence in India through development, manufacturing and commercial operations in the formulation segment.

According to a trade source, Sandoz’s popular brands in India include Calcium Sandoz, Adelphane, Curam, Ebutol, etc.

According to a sector analyst, though the move is astonishing as India is a low-cost destination for API development, in the case of it may be relatively less significant as the company would be looking at captive use. “might have done a cost-benefit analysis which suggested the move,” he said. “This could be because the company aims to focus on drug development and R&D in formulations. In that case, it makes sense for the company to even get API from others, it will save them a lot of energy and resources. Plus, the focus will remain on formulations.”

Of the country’s Rs 65,000-crore pharma market, 15 per cent is accounted for by API. Although over the last few years, increasing API imports from China has posed significant threat to the Indian API market, various drug makers like Dr Reddy’s Labs, Cipla and Ranbaxy are still manufacturing both APIs and formulations. However, many of these companies have reduced their focus on API as landed price for some Chinese APIs in India is less than their corresponding cost of production here.

image
Business Standard
177 22

Sandoz shuts unit near Mumbai

Sandoz, the generic arm of Swiss drug maker Novartis, recently closed its facility developing active pharmaceutical ingredients (API) near Mumbai, a person close to the development told Business Standard. This facility was part of the company’s global development centre in India.

confirmed the move. In response to an e-mail query, India Vice-Chairman & Managing Director said, “The decision was taken as part of a project portfolio optimisation within Global Development.”

According to the source, however, financial pressure on the parent company triggered the move. “The facility employed 50 odd people, and most of them were asked to look for jobs,” he said.

Shahani maintained the impact on employees was minimised by redeploying people in other parts of the company here.

Global Development in India employed around 200-250 people, of which 50, who were engaged in API development activities in Kalwa near Mumbai, were given three-months' notice in April, the source said. Although the company retained its formulation development activities and employees engaged in the same, the closure of API development in India happened around June-July, he said.

While Sandoz’s API development activities from India are now consolidated into two other development centres in Europe, the company continues to have its presence in India through development, manufacturing and commercial operations in the formulation segment.

According to a trade source, Sandoz’s popular brands in India include Calcium Sandoz, Adelphane, Curam, Ebutol, etc.

According to a sector analyst, though the move is astonishing as India is a low-cost destination for API development, in the case of it may be relatively less significant as the company would be looking at captive use. “might have done a cost-benefit analysis which suggested the move,” he said. “This could be because the company aims to focus on drug development and R&D in formulations. In that case, it makes sense for the company to even get API from others, it will save them a lot of energy and resources. Plus, the focus will remain on formulations.”

Of the country’s Rs 65,000-crore pharma market, 15 per cent is accounted for by API. Although over the last few years, increasing API imports from China has posed significant threat to the Indian API market, various drug makers like Dr Reddy’s Labs, Cipla and Ranbaxy are still manufacturing both APIs and formulations. However, many of these companies have reduced their focus on API as landed price for some Chinese APIs in India is less than their corresponding cost of production here.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard